SI-BONE, Inc. (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 9,967 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $13.84, for a total transaction of $137,943.28. Following the completion of the transaction, the chief executive officer now directly owns 492,923 shares in the company, valued at $6,822,054.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
SI-BONE Price Performance
Shares of SIBN stock traded down $0.14 on Tuesday, reaching $14.18. The company had a trading volume of 234,859 shares, compared to its average volume of 400,173. The stock has a market capitalization of $591.16 million, a PE ratio of -13.01 and a beta of 1.20. The company has a quick ratio of 8.12, a current ratio of 9.17 and a debt-to-equity ratio of 0.22. The business’s 50-day moving average is $14.13 and its 200 day moving average is $15.50. SI-BONE, Inc. has a one year low of $11.76 and a one year high of $23.25.
SI-BONE (NASDAQ:SIBN – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The firm had revenue of $39.97 million for the quarter, compared to analyst estimates of $38.95 million. During the same period last year, the firm posted ($0.30) earnings per share. Equities research analysts forecast that SI-BONE, Inc. will post -0.89 EPS for the current fiscal year.
Hedge Funds Weigh In On SI-BONE
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the stock. Truist Financial lowered their price target on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. JMP Securities reissued a “market outperform” rating and set a $32.00 price target on shares of SI-BONE in a report on Tuesday, May 7th. Morgan Stanley reduced their price target on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Needham & Company LLC lowered their price target on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SI-BONE presently has a consensus rating of “Buy” and an average price target of $23.00.
About SI-BONE
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
See Also
- Five stocks we like better than SI-BONE
- Stock Sentiment Analysis: How it Works
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What is the NASDAQ Stock Exchange?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- How to Read Stock Charts for Beginners
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.